今年以来，国内不少A股、港股创新药企凭借潜在BD（商务拓展）预期被投资者追捧，股价节节攀升。特别是一些被视作与跨国药企合作或被收购潜在标的的企业，其股价涨幅位居板块前列。 近日，辉瑞宣布，拟斥资73亿美元收购减肥药物开发商Metsera。这一大手笔收购被普遍视为辉瑞重返减肥药赛道的重要信号，但也引发了国内资本市场的连锁反应。A股市场上，多家减肥药概念股的股价因此承压。 当辉瑞选择了...
Source Link今年以来，国内不少A股、港股创新药企凭借潜在BD（商务拓展）预期被投资者追捧，股价节节攀升。特别是一些被视作与跨国药企合作或被收购潜在标的的企业，其股价涨幅位居板块前列。 近日，辉瑞宣布，拟斥资73亿美元收购减肥药物开发商Metsera。这一大手笔收购被普遍视为辉瑞重返减肥药赛道的重要信号，但也引发了国内资本市场的连锁反应。A股市场上，多家减肥药概念股的股价因此承压。 当辉瑞选择了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.